**Name of journal: *World Journal of Gastroenterology***

**ESPS Manuscript NO: 23642**

**Manuscript Type: ORIGINAL ARTICLE**

***Prospective Study***

**Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer**

Zhou Y *et al*. OLGA stage in predicting EGC

Ying Zhou, Hai-Yan Li, Jing-Jing Zhang, Xiao-Yu Chen, Zhi-Zheng Ge, Xiao-Bo Li

**Ying Zhou, Hai-Yan Li, Jing-Jing Zhang, Xiao-Yu Chen, Zhi-Zheng Ge, Xiao-Bo Li**, Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai 200001, China

**Author contributions:** Zhou Y participated in study design and data collection, performed oversight of the study and statistical analysis, and drafted and revised the manuscript; Li HY participated in study design and data collection; Zhang JJ participated in data collection and modified the manuscript for important intellectual content; Chen XY performed data collection and analysis; Ge ZZ performed data collection and analysis; Li XB participated in study design and data collection, performed statistical analysis, and modified the manuscript for important intellectual content; all authors read and approved the final manuscript.

**Institutional review board statement:** All biopsy specimens were taken after informed consent, and ethical permission was obtained from each of the patients who participated in the study.

**Clinical trial registration statement:** This study is registered at <https://register.clinicaltrials.gov/> under the identification number NCT02562976.

**Informed consent statement:** All study participants, or their legal guardian, provided written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare no conflict of interests for this article.

**Data sharing statement:** No additional unpublished data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Xiao-Bo Li,** **MD, PhD,** Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China. [lxb\_1969@163.com](mailto:lxb_1969@163.com)

**Telephone:** +86-21-58394262

**Fax:** +86-21-58394262

**Received:** December 7, 2015

**Peer-review started:** December 8, 2015

**First decision:** January 13, 2016

**Revised:** January 25, 2016

**Accepted:** February 20, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIMS:** To assess Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stages in prognosis.

**METHODS:** A prospective study was conducted with 71 patients with early gastric cancer (EGC) and 156 patients with non-EGC. All patients underwent endoscopic examination and systematic biopsy. Outcome measures were assessed and compared, including the Japanese endoscopic gastric atrophy (EGA) classification method and the modified OLGA method as well as the modified OLGIM method. *Helicobacter pylori* (*H. pylori*) status was determined for all study participants. Stepwise logistic regression modeling was performed to analyze correlations between EGC and the EGA, OLGA and OLGIM methods.

**RESULTS:** For patients with EGC and patients with non-EGC, the proportion of moderate-to-severe EGA cases was 64.8% and 44.9% respectively (*P* = 0.005), the proportion of OLGA stage III-IV cases was 52.1% and 22.4% respectively (*P* < 0.001), and the proportion of OLGIM stage III-IV cases was 42.3% and 19.9% respectively (*P* < 0.001). OLGA stage and OLGIM stage were significantly related to EGA classification; specifically, logistic regression modeling showed significant correlations between EGC and moderate-to-severe EGA (OR = 1.95, 95% CI: 1.06–3.58, *P* = 0.031) and OLGA stage III-IV (OR = 3.14, 95%CI: 1.71–5.81, *P* < 0.001), but no significant correlation between EGC and OLGIM stage III-IV (*P* = 0.781). *H. pylori* infection rate was significantly higher in patients with moderate-to-severe EGA (75.0% *vs* 54.1%, *P* = 0.001) or OLGA/OLGIM stage III-IV (OLGA: 83.6% *vs* 55.8%, *P* < 0.001; OLGIM: 83.6% *vs* 57.8%, *P* < 0.001).

**CONCLUSION:** OLGA classification is optimal for EGC screening, a surveillance program including OLGA stage and *H. pylori* infection status may facilitate early detection of gastric cancer.

**Key words:** Early gastric cancer; Operative Link on Gastritis Assessment / Operative Link on Gastric Intestinal Metaplasia Assessment stage; Endoscopic gastric atrophy classification; Screening; Endoscopy

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) have been proven separately as effective methods to evaluate severity of gastric atrophy and intestinal metaplasia. However, these methods have not been compared for prognosticating neoplastic development. This study compared the correlations of these three methods with early gastric cancer (EGC) and found that OLGA classification is optimal for EGC screening. A surveillance program based on OLGA stage and *Helicobacter pylori* infection status may represent a practical approach for detecting more gastric cancers at an early stage.

Zhou Y, Li HY, Zhang JJ, Chen XY, Ge ZZ, Li XB.Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide[[1](#_ENREF_1)]. The prognosis of GC is meaningfully associated with tumor stage, as highlighted by the 5-year overall survival rate of patients with early gastric cancer (EGC) exceeding 90%[[2](#_ENREF_2),[3](#_ENREF_3)]. The presence of atrophic gastritis (defined as loss of appropriate gland function), intestinal metaplasia (defined as replacement of gastric epithelium by intestinal-type epithelium, IM) and *Helicobacter pylori* (*H. pylori*) infection are well-known risk factors of GC. As only a small proportion of patients with atrophic gastritis and IM progress to GC[[4](#_ENREF_4)], identifying the characteristics of the background mucosa in EGC may help clinicians to select a subgroup of patients who may benefit from a surveillance program.

In recent years, the Operative Link on Gastritis Assessment (OLGA), which is based on the histopathology findings of biopsy specimens, was proposed as an effective method to rank gastritis into stages with corresponding carcinoma risks[[5](#_ENREF_5),[6](#_ENREF_6)]. It has been reported that a high-risk stage (defined as stages III or IV of the OLGA classification) is strongly correlated with high risk of GC[[7](#_ENREF_7),[8](#_ENREF_8)]. However, in consideration of the low interobserver agreement of OLGA classification, the Operative Link on Intestinal Metaplasia Assessment (OLGIM) was developed as an alternative, and was subsequently recommended as an effective method to predict GC risk due to its higher interobserver agreement and strong association with the OLGA stage[[9](#_ENREF_9),[10](#_ENREF_10)].

The endoscopic gastric atrophy (EGA) assessment that uses Kimura–Takemoto classification was first applied in a study of Japanese subjects to evaluate the extent of endoscopic atrophic border (EAB) and the severity of gastric atrophy[[11](#_ENREF_11)]. Subsequent study showed that moderate-to-severe grade of EGA was closely associated with an increased risk of GC[[12](#_ENREF_12)]. EGA is regarded as an assessment of endoscopic gastric atrophy, in contrast to the OLGA and OLGIM methods which are identified as the assessments of histologic atrophy and IM. While all three methods have been proven effective in assessing gastric atrophy and predicting the development of GC, their use remains limited and has not extended worldwide. The OLGA and OLGIM classifications are applied primarily in Europe and America; on the other hand, the EGA assessment is applied primarily in Japan and Vietnam. None of these three evaluation methods has been widely applied in China and other Asian countries, despite the fact that they harbor a high prevalence of GC.

Determining the optimal assessment method for predicting EGC makes sense for both patient care and allocation of medical resources. To the best of our knowledge, no research study to date has reported a comparative analysis of the associations between the three evaluation methods and EGC; as such, the relationship between EGA assessment and the OLGA/OLGIM stages remains unclear. We designed this prospective study to evaluate the characteristics of the background mucosa of EGC using three criterions, ultimately to investigate whether the EGA, OLGA or OLGIM methods has the highest correlation with EGC so that the optimal means of assessment can be used in development of an appropriate surveillance program for detecting EGC in China.

**MATERIALS AND METHODS**

***Patients and classification***

The study was conducted prospectively at Shanghai Ren Ji Hospital from May 2013 through July 2015. Consecutive patients, ranging in age from 40-years-old to 80-years-old, with diagnosis of functional dyspepsia or suspicion of EGC and who underwent esophagogastroduodenoscopy were recruited to the study. Patients were excluded from study participation based upon diagnosis of advanced GC, order or receipt of post-subtotal gastrectomy, or presence of any conditions that may interfere with clinical examination or treatment, such as acute upper gastrointestinal bleeding and severe systemic diseases (*e.g.,* a severe cardiac condition, serious infection, or renal failure). Patients who lacked histology data were also excluded.

The study protocol was approved by the local ethics committee, and all patients provided written informed consent. Patients were selected and classified into two groups. Patients with pathology diagnosis of EGC or high-grade neoplasia (HGN) (category 4-5 according to the revised Vienna classification)[[13](#_ENREF_13)] were defined as the EGC group. Patients with pathology diagnosis of non-gastritis, gastritis or low-grade neoplasia (LGN) (revised Vienna category 1-3) were defined as the non-EGC group.

***Endoscopic procedure***

All patients were examined by a single experienced endoscopist, using a conventional endoscope (GIF-H260; Olympus Medical Systems, Tokyo, Japan), a magnifying endoscope (GIF-H260 Z; Olympus Medical Systems), and an electric endoscopic system (EVIS 260 Spectrum; Olympus Medical Systems). All patients were originally diagnosed using the Kimura-Takemoto EGA assessment[[11](#_ENREF_11)] (Figure 1). The extent of atrophic gastritis was categorized according to the following two primary patterns: closed-type gastritis (C-type) and open-type gastritis (O-type). For the C-type, C1 sub-categorization represented highly localized antral gastritis, C2 sub-categorization represented increasing extension through the lesser curvatures, and C3 sub-categorization represented increasing extension through the greater curvatures. For the O-type, in which the gastritis reached cardia, O1 sub-categorization indicated reach to lesser curvatures, O2 sub-categorization indicated reach to half of the stomach, and O3 sub-categorization indicated extensive atrophic gastritis that affected almost the entire stomach. According to the patient’s EGA classification, the endoscopic atrophic pattern was divided into the following three degrees: mild (C1-C2), moderate (C3-O1) and severe (O2-O3). Then, biopsy samples (*n*) were obtained for histology from the following standardized sites: antrum (*n* = 3, including 1 for exclusive use in the rapid urease test (RUT) (Pronto Dry™; Medical Instruments Corporation, Solothurn, Switzerland) and corpus (*n* = 2, including 1 from the lesser curvature and 1 from the greater curvature). If a suspicious lesion was found, 2-3 extra biopsy samples were obtained from the lesion.

***Treatment***

Patients with suspected EGC or with diagnosis of intraepithelial neoplasia by pathology were examined by magnifying endoscopy with narrow-band imaging (ME-NBI). The treatment for each patient was determined according to results from conventional endoscope (CE) and ME-NBI, as well as biopsy pathologic diagnoses. When the biopsy pathology turned out to be gastritis or LGN (revised Vienna category 1-3), the patients received follow-up. For those diagnosed with HGN and GC (revised Vienna category 4-5) by biopsy pathology, endoscopic submucosal dissection (ESD) or surgery were chosen according to the indications of endoscopic resection (ER)[[13](#_ENREF_13)].

***Histopathology***

The retrieved tissues were fixed in formalin (10%) and embedded in paraffin. All biopsy specimens were examined by a single experienced pathologist, blinded to the endoscopic diagnosis, using the World Health Organization classification of tumors (digestive system)[[14](#_ENREF_14)] and the revised Vienna classification[[13](#_ENREF_13)]. Gastric adenocarcinomas were sub-divided into D-type (well or moderately differentiated adenocarcinoma or papillary adenocarcinoma) and UD-type (mucinous cell carcinoma, signet-ring cell carcinoma, or poorly differentiated adenocarcinoma). If both characteristics were present, the lesion was regarded as UD-type. Atrophic gastritis and IM[[6](#_ENREF_6)] were scored using a visual analog scale based on the updated Sydney system[[15](#_ENREF_15)], in which 0 = absent, 1 = mild, 2 = moderate, and 3 = severe. Presence of atrophic gastritis and stage of IM were determined according to the modified OLGA stage system and the modified OLGIM stage system, without biopsy from incisura angularis[[16](#_ENREF_16)].

***H. pylori* *evaluation***

For patients who underwent esophagogastroduodenoscopy, biopsy samples were obtained from antrum (*n* = 3, 1 for RUT and 2 for *H. pylori* detection) and from corpus (*n* = 2, both for *H. pylori* detection). For *H. pylori* detection, sections were stained with modified Giemsa and histologically evaluated. In addition, peripheral blood was collected to determine *H. pylori* IgG antibody titers by enzyme-linked immunosorbent assay (ELISA) (*H. pylori*-EIA-Well; Radim, Rome, Italy). Any two positive findings among the tests of four biopsy sites, RUT, and anti-*H. pylori* IgG were considered as having a positive *H. pylori* status. Patients with only with one positive result were considered as having an inconclusive *H. pylori* status. Only those patients with all tests having negative results were considered as negative (non-infected) *H. pylori* status.

***Statistical analysis***

All statistical analyses were performed using SPSS version 19.0 statistical software (SPSS Inc., Chicago, IL, United States). Continuous parameters were expressed as mean ± SD, and discrete parameters were expressed as numbers and percentages. Differences between the two groups were evaluated by Pearson’s 2 test, Mann-Whitney Wilcoxon test and Student’s *t*-test, as appropriate. A logistic regression model (stepwise forward procedure) was used for correlation analysis between EGA, OLGA, OLGIM and EGC. All *P* values reported are two-sided, and a *P* value of < 0.05 was considered statistically significant.

**RESULTS**

***Clinicopathological characteristics***

Overall, 227 patients were enrolled in the study. The clinicopathological characteristics of these patients, in the EGC group (*n* = 71) and the non-EGC group (*n* = 156), are summarized in Table 1. The EGC group had a total of 75 EGC lesions (21.9 ± 9.3 mm mean diameter), and 66 of the patients in this group underwent ESD treatment while 5 underwent surgery. Of the 75 EGC lesions, 72 (96.0%) were differentiated-type and 3 (4.0%) were undifferentiated-type. As for the tumor size, 14 (18.7%) were ≤ 1 cm, 33 (44%) were 1-2 cm, 15 (20%) were 2-3 cm and 13 (17.3%) were > 3 cm. Moreover, 70 (93.3%) of the tumors were intramucosal and 5 (6.7%) were submucosal.

The mean patient age, sex, *H. pylori* infection rate, and atrophic rate were not significantly different between the EGC and non-EGC groups. On the other hand, the EGA classification, OLGA stage, OLGIM stage, IM rate and IM type were significantly different between the two groups.

***EGA classification and*** ***OLGA/OLGIM stage***

As shown in Table 2, the proportion of moderate-to-severe EGA cases in the EGC group and the non-EGC group were 64.8% (46/71) and 44.9% (70/156). The proportions of OLGA gastritis stage III-IV cases in the EGC group and the non-EGC group were 52.1% (37/71) and 22.4% (35/156). The proportions of OLGIM stage III-IV cases in the EGC group and the non-EGC group were 42.3% (30/71) and 19.9% (31/156).

Relation between EGA classification and OLGA/OLGIM stage is summarized in Table 3. OLGA stage and OLGIM stage were significantly related to EGA classification. Table 4 shows the relation between OLGA stage and OLGIM stage. For 128 of the total 227 cases (56.4%), low-risk stages (0 +I+II) and high-risk stages (III+IV) were consistent when either the OLGA or OLGIM criteria were used. Ninety-nine of the total 227 cases (43.6%) staged inconsistently, including 80 patients (35.2%) who were down-staged by OLGIM criteria compared with OLGA criteria, with 20 patients (8.8%) who were considered as low-risk when the OLGIM criteria were used but as high-risk when the OLGA criteria were used, and 19 patients who were down-staged by OLGA criteria compared with OLGIM criteria. As for correlation between EGA, OLGA, OLGIM and EGC, logistic regression modeling showed that moderate-to-severe EGA and OLGA stage III-IV were significantly associated with EGC (Table 5).

***H. pylori infection***

The EGC group had a slightly higher *H. pylori* infection rate than the non-EGC group (70.4% *vs* 61.5%), but the difference was not significant (*P* = 0.195) (Table 1). The *H. pylori* infection rate in moderate-to-severe EGA patients was significantly higher than that in the none-to-mild EGA patients (75.0% *vs* 54.1%, *P* = 0.001). In addition, the *H. pylori* infection rate in OLGA/OLGIM stage III-IV patients was significantly higher than that in the OLGA/OLGIM stage 0-II patients (OLGA: 83.6% *vs* 55.8%, *P* < 0.001; OLGIM: 83.6% *vs* 57.8%, *P* < 0.001). However, the *H. pylori* infection rate in the patients with complete IM was not different from that in the patients with incomplete IM (68.5% *vs* 68.0%, *P* = 0.949) (Table 6).

**DISCUSSION**

China has high prevalence of GC, reflecting its huge population, distinctive dietary (high-salt) structure and high *H. pylori* infection rate. Recognizing risk factors of EGC and establishing an appropriate surveillance system for patients with high risk of GC will help to lengthen the survival time of patients and reduce waste of social resources. In the current study, we found that moderate-to-severe EGA and high-risk (III⁄IV) OLGA/OLGIM stages had a remarkable correlation with EGC, and these results are consistent with the published literature[[7-10](#_ENREF_7),[12](#_ENREF_12),[17](#_ENREF_17)]. Rugge *et al*[[10](#_ENREF_10)] stated that most HGN or invasive gastric neoplasias were consistently connected with high-risk OLGA/OLGIM stages (97.6% for OLGA stages, and 92.7% for OLGIM stages); however, in our study, 47.9% (34/71) and 57.7% (41/71) patients with EGC were staged as low-risk (0-II) according to the modified OLGA/OLGIM methods. In addition to the differences of pathological diagnosis and race of our study population, another important difference was our strategy of obtaining and using only four gastric biopsy specimens for staging by the modified OLGA/OLGIM methods. Despite the fact that five standard biopsy specimens have been recommended by the updated Sydney system (two from the antrum, two from the corpus, and one from the incisura)[[15](#_ENREF_15)], whether biopsy samples from the incisura angularis may provide extra clinical information useful towards determining the extent of premalignant conditions remains an unresolved controversy[[18](#_ENREF_18)]. Current guidelines suggested at least four biopsies (two from the antrum, and two from the corpus) for adequate staging[[19](#_ENREF_19)]. Marcos-Pinto *et al*[[16](#_ENREF_16)] applied a modified OLGA/OLGIM staging system, with exclusion of biopsy of the incisura, and showed a downgrade of stages in comparison with standard OLGA stages. We took only four gastric biopsy specimens, which might have resulted in downgrade of high-risk OLGA/OLGIM stages. Our study also showed the existence of IM and the incomplete IM subtype to be significantly correlated with EGC, and these findings are consistent with those from other studies[[20](#_ENREF_20),[21](#_ENREF_21)].

Quach *et al*[[22](#_ENREF_22)] studied the relation between EGA classification and OLGA stage using 280 patients with functional dyspepsia. The results indicated a significant association between moderate-to-severe EGA and high-risk OLGA stage and extensive IM; our findings in the current study confirmed this conclusion. Moreover, the present study investigated the relation between OLGA stage and OLGIM stage. Approximately one-third of the cases were down-staged by OLGIM criteria, as compared with OLGA criteria, and less than one-tenth of the cases were considered as low-risk using the OLGIM criteria and as high-risk according to OLGA. Because a down-stage existed using OLGIM criteria, as compared with OLGA criteria[[10](#_ENREF_10)], and more than one-half of the patients with EGC in our study were staged as 0-II by OLGIM, it may be prudent to consider that low OLGIM stages are simply considered equal to low risk for EGC.

The three assessments used to evaluate gastric atrophy and IM were all risk factors of EGC; nevertheless, they have their own characteristics. EGA focuses on the recognition of the endoscopic atrophic border and its range in the stomach. As the endoscopic gastric atrophy classification, EGA could be assessed in real-time as patients are undergoing endoscopy. Furthermore, EGA is intuitive and can be evaluated without taking biopsy specimens, which reduces the risk of gastric bleeding as well as saves costs associated with performance of the biopsy procedure. However, EGA is subjective and may result in designation of a different stage by different endoscopists, regardless of whether they are experienced or not. One recent report examined interobserver and intraobserver agreement for EGA[[23](#_ENREF_23)]. The result showed that although intraobserver agreement for gastric mucosa atrophy was good to excellent (kappa value: 0.585-0.871), the interobserver agreement was only moderate for experienced endoscopists (kappa value: 0.29-0.474). The low interobserver agreement may give rise to low reproducibility of endoscopic findings, and may influence the detection of EGC to some extent. On the contrary, histologic atrophy and IM assessments based on OLGA/OLGIM system are more objective, and they are designated by pathologists who are blinded to the patients’ clinic information and whose material for assessment is subject to less interference than that of endoscopists. The interobserver agreement of OLGA/OLGIM by expert pathologists was reportedly higher than that for EGA[[9](#_ENREF_9),[24](#_ENREF_24)]. However, OLGA/OLGIM staging depends on the biopsy specimens taken by endoscopists, which may be down-staged in cases when severe lesions were missed. That might be why, in the present study, the percentage of OLGA/OLGIM stage III-IV cases was lower in EGC than in moderate-to-severe EGA. We analyzed the correlation between EGC and endoscopic, histologic gastritis. The odds ratio of high-risk EGA, OLGA and OLGIM was 2.26, 3.76 and 2.95, respectively. In view of the tight relation of the three methods, stepwise logistic regression modeling was performed to determine which classification performs better in suggesting the occurrence of EGC. It showed that moderate-to-severe EGA and OLGA stage III-IV were prominently related to EGC (*P* = 0.031 for EGA and *P* < 0.001 for OLGA), with the odds ratio of high-risk EGA and OLGA being 1.95 and 3.14 respectively. Thus, OLGA stage III-IV appeared to be more relevant to the occurrence of EGC. In addition, since *H. pylori* infection is considered high risk for GC[[25](#_ENREF_25),[26](#_ENREF_26)][25] and has been demonstrated as significantly related to high-risk OLGA/OLGIM stages[[27](#_ENREF_27)] and to moderate-to-severe EGA (the present study), we emphasized the importance of *H. pylori* infection in the detection of EGC. Considering the advantages and disadvantages of the three methods, we suggest that OLGA classification combined with *H. pylori* detectionbe put into routine use in a surveillance program for EGC.

Up to now, the suitable surveillance intervals for patients under precancerous conditions remain controversial. According to the recent guidelines[[19](#_ENREF_19)], endoscopic surveillance is recommended for patients with extensive atrophic gastritis or IM, who should obtain follow-up every 3 years. In contrast, some researchers from Japanhave suggested that patients with extensive atrophic gastritis or IM obtain follow-up every 1 year, those with moderate atrophic gastritis every 2 years, and those with none-to-mild every 3 years[[28](#_ENREF_28),[29](#_ENREF_29)]. Based on the findings from the present study, although moderate-to-severe EGA and high-risk OLGA/OLGIM stages were all high-risk factors of EGC, the OLGA classification may be more appropriate for EGC screening. We suggest that patients more than 40-years-old undergo upper gastrointestinal endoscopy for GC screening, with OLGA stage being detected in the meanwhile. The surveillance intervals for patients with OLGA stage III-IV need to be shortened, even when there is no obvious lesion, and endoscopists should be sufficiently cautious and take more biopsy specimens if necessary in order to avoid missed diagnosis of EGC. Prospective studies are needed to investigate the appropriate surveillance intervals for patients with OLGA stage III-IV.

This study had several limitations. First, all the endoscopic assessments were performed by a single highly experienced endoscopist, and all the histopathological diagnoses were made by a single experienced pathologist, which may lead to deviations of data analysis. Second, this was a single-center study; therefore, we cannot exclude the possibility of selection bias. However, to the best of our knowledge, this is the first study to iden­tify that OLGA stage is more appropriate for predicting EGC than OLGIM stage and EGA classification, which can further help in establishment of a thorough surveillance program for EGC.

In conclusion, our study showed that moderate-to-severe EGA and high-risk OLGA/OLGIM stages are all high-risk factors of EGC. The three assessments had tight relation with each other, and *H. pylori* infection was significantly associated with high-risk stage of both endoscopic and histologic atrophy and IM. However, we suggest OLGA classification as the optimal method for EGC screening. A surveillance program including OLGA stage and *H. pylori* infection is expected to be a practical approach that will help to achieve greater detection of gastric cancers at an early stage.

**ACKNOWLEDGMENTS**

We thank Dr. Ye Chen and our staff at the Department of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University for their great support.

**COMMENTS**

***Background***

Japanese endoscopic gastric atrophy (EGA) classification, Operative Link on Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) have been proven separately as effective methods to evaluate severity of gastric atrophy and intestinal metaplasia. However, these methods have not been compared for prognosticating neoplastic development. The present study was designed to compare these three methods, so as to select the optimal method for early gastric cancer (EGC) screening.

***Research frontiers***

There is increasing focus on the correlations between gastric atrophy and intestinal metaplasia with GC. EGA classification is considered as endoscopic gastric atrophy assessment, while OLGA/OLGIM is considered as histologic gastric atrophy/intestinal metaplasia assessments. Recent investigations have shown that moderate-to-severe EGA and high-risk OLGA/OLGIM stages are high-risk factors of EGC.

***Innovations and breakthroughs***

The present study analyzes the advantages as well as disadvantages of endoscopic and histologic gastric atrophy or intestinal metaplasia (EGA classification, OLGA/OLGIM stages), and compares the correlation between EGC and these three methods. The findings show that OLGA classification is optimal for EGC screening. It is suggested that the OLGA classification be adopted to help detect more gastric cancers at an early stage.

***Applications***

This study provides additional evidence supporting the importance of OLGA stage in predicting the development of EGC, which may lead to development of an appropriate surveillance program for EGC screening.

***Terminology***

OLGA and OLGIM are gastritis staging systems that primarily rank the risk of GC according to the ex­tent and severity of gastric atrophy and intestinal metaplasia. EGA assessment, first defined by Kimura-Takemoto and mostly used in Japan, is divided into six types according to the ex­tent of gastric atrophy detected under endoscopic observation.

***Peer-review***

The authors evaluated the characteristics of background mucosa in patients with EGC by using different classifications (EGA, OLGA and OLGIM) and compared the correlations between these three methods and EGC. They concluded that all three methods are risk factors of EGC and OLGA classification is optimal for EGC screening.

**REFERENCES**

1 IARC, Globocan 2012. World Health Organization. Paris, 2014 Available from: URL: http: //globocan.iarc.fr/Default.aspx

2 **Fock KM**, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, Uemura N, Kim JG, Kim N, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J. Asia-Pacific consensus guidelines on gastric cancer prevention. *J Gastroenterol Hepatol* 2008; **23**: 351-365 [PMID: 18318820 DOI: 10.1111/j.1440-1746.2008.05314.x]

3 **Ono H**, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001; **48**: 225-229 [PMID: 11156645]

4 **de Vries AC**, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology* 2008; **134**: 945-952 [PMID: 18395075 DOI: 10.1053/j.gastro.2008.01.071]

5 **Rugge M**, Genta RM. Staging and grading of chronic gastritis. *Hum Pathol* 2005; **36**: 228-233 [PMID: 15791566]

6 **Rugge M**, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, Genta RM, Graham DY, Hattori T, Malfertheiner P, Nakajima S, Sipponen P, Sung J, Weinstein W, Vieth M. OLGA staging for gastritis: a tutorial. *Dig Liver Dis* 2008; **40**: 650-658 [PMID: 18424244 DOI: 110.1016/j.dld.2008.02.030]

7 **Rugge M**, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, Basso D, Plebani M, Graham DY. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. *Aliment Pharmacol Ther* 2010; **31**: 1104-1111 [PMID: 20180784 DOI: 10.1111/j.1365-2036.2010.04277.x]

8 **Quach DT**, Le HM, Nguyen OT, Nguyen TS, Uemura N. The severity of endoscopic gastric atrophy could help to predict Operative Link on Gastritis Assessment gastritis stage. *J Gastroenterol Hepatol* 2011; **26**: 281-285 [PMID: 21261717 DOI: 10.1111/j.1440-1746.2010.06474.x]

9 **Capelle LG**, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NC, Kuipers EJ. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. *Gastrointest Endosc* 2010; **71**: 1150-1158 [PMID: 20381801 DOI: 10.1016/j.gie.2009.12.029]

10 **Rugge M**, Fassan M, Pizzi M, Farinati F, Sturniolo GC, Plebani M, Graham DY. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. *World J Gastroenterol* 2011; **17**: 4596-4601 [PMID: 22147965 DOI: 10.3748/wjg.v17.i41.4596]

11 **Kimura K**, Satoh K, Ido K, Taniguchi Y, Takimoto T, Takemoto T. Gastritis in the Japanese stomach. *Scand J Gastroenterol Suppl* 1996; **214**: 17-20; discussion 21-3 [PMID: 8722400]

12 **Take S**, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. *J Gastroenterol* 2007; **42** Suppl 17: 21-27 [PMID: 17238021 DOI: 10.1007/s00535-006-1924-9]

13 **Dixon MF**. Gastrointestinal epithelial neoplasia: Vienna revisited. *Gut* 2002; **51**: 130-131 [PMID: 12077106]

14 **Hamilton SR**, Aaltonen LA, Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours. Lyon (France): IARC Press, 2000

15 **Dixon MF**, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996; **20**: 1161-1181 [PMID: 8827022]

16 **Marcos-Pinto R**, Carneiro F, Dinis-Ribeiro M, Wen X, Lopes C, Figueiredo C, Machado JC, Ferreira RM, Reis CA, Ferreira J, Pedroto I, Areias J. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. *Aliment Pharmacol Ther* 2012; **35**: 1451-1459 [PMID: 22548492 DOI: 10.1111/j.1365-2036.2012.05111.x]

17 **Satoh K**, Osawa H, Yoshizawa M, Nakano H, Hirasawa T, Kihira K, Sugano K. Assessment of atrophic gastritis using the OLGA system. *Helicobacter* 2008; **13**: 225-229 [PMID: 18466398 DOI: 10.1111/j.1523-5378.2008.00599.x]

18 **Eriksson NK**, Färkkilä MA, Voutilainen ME, Arkkila PE. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. *Endoscopy* 2005; **37**: 532-536 [PMID: 15933925 DOI: 10.1055/s-2005-861311]

19 **Dinis-Ribeiro M**, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy* 2012; **44**: 74-94 [PMID: 22198778 DOI: 10.1055/s-0031-1291491]

20 **Filipe MI**, Muñoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. *Int J Cancer* 1994; **57**: 324-329 [PMID: 8168991]

21 **Cassaro M**, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. *Am J Gastroenterol* 2000; **95**: 1431-1438 [PMID: 10894575]

22 **Quach DT**, Le HM, Hiyama T, Nguyen OT, Nguyen TS, Uemura N. Relationship between endoscopic and histologic gastric atrophy and intestinal metaplasia. *Helicobacter* 2013; **18**: 151-157 [PMID: 23167960 DOI: 10.1111/hel.12027]

23 **Miwata T**, Quach DT, Hiyama T, Aoki R, Le HM, Tran PL, Ito M, Tanaka S, Arihiro K, Uemura N, Chayama K. Interobserver and intraobserver agreement for gastric mucosa atrophy. *BMC Gastroenterol* 2015; **15**: 95 [PMID: 26239636 DOI: 10.1186/s12876-015-0327-x]

24 **Isajevs S**, Liepniece-Karele I, Janciauskas D, Moisejevs G, Putnins V, Funka K, Kikuste I, Vanags A, Tolmanis I, Leja M. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. *Virchows Arch* 2014; **464**: 403-407 [PMID: 24477629 DOI: 10.1007/s00428-014-1544-3]

25 Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. *IARC Monogr Eval Carcinog Risks Hum* 1994; **61**: 1-241 [PMID: 7715068]


26 **Helicobacter and Cancer Collaborative Group.** Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. *Gut* 2001; **49**: 347-353 [PMID: 11511555]

27 **Nam JH**, Choi IJ, Kook MC, Lee JY, Cho SJ, Nam SY, Kim CG. OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population. *Helicobacter* 2014; **19**: 81-89 [PMID: 24617667 DOI: 10.1111/hel.12112]

28 **Miki K**. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method". *Proc Jpn Acad Ser B Phys Biol Sci* 2011; **87**: 405-414 [PMID: 21785258 DOI: 10.2183/pjab.87.405]

29 **Yoshihara M**, Hiyama T, Yoshida S, Ito M, Tanaka S, Watanabe Y, Haruma K. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. *Scand J Gastroenterol* 2007; **42**: 760-764 [PMID: 17505999 DOI: 10.1080/00365520601097351]

**P-Reviewer:** Marrelli D **S-Editor:** Qi Y **L-Editor: E-Editor:**



**Figure 1 Endoscopic atrophic pattern described by Kimura-Takemoto[**[**11**](#_ENREF_11)**].** The spread of atrophic gastritis is divided into closed-type gastritis (C-type) and open-type gastritis (O-type). C-1 represents highly localized antral gastritis, and C-2 and C-3 represent increasing extension through the lesser curvatures and greater curvatures, respectively. O-type indicates gastritis reaching cardia, with O-1 reaching lesser curvatures, O-2 reaching half of the stomach, and O-3 having extensive atrophic gastritis, affecting almost the entire stomach.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Atrophy score | | Corpus | | | |
| No atrophy  (score 0) | Mild atrophy  (score 1) | Moderate atrophy  (score 2) | Severe atrophy  (score 3) |
| Antrum | No atrophy  (score 0) | STAGE 0 | STAGE I | STAGE II | STAGE II |
| Mild atrophy  (score 1) | STAGE I | STAGE I | STAGE II | STAGE III |
| Moderate atrophy  (score 2) | STAGE II | STAGE II | STAGE III | STAGE IV |
| Severe atrophy  (score 3) | STAGE III | STAGE III | STAGE IV | STAGE IV |

**Figure 2 Modified operative link for gastritis assessment staging frame (with exclusion of the biopsies from incisura angularis)[**[**16**](#_ENREF_16)**].**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| IM score | | Corpus | | | |
| No IM  (score 0) | Mild IM  (score 1) | Moderate IM  (score 2) | Severe IM  (score 3) |
| Antrum | No IM  (score 0) | STAGE 0 | STAGE I | STAGE II | STAGE II |
| Mild IM  (score 1) | STAGE I | STAGE I | STAGE II | STAGE III |
| Moderate IM  (score 2) | STAGE II | STAGE II | STAGE III | STAGE IV |
| Severe IM  (score 3) | STAGE III | STAGE III | STAGE IV | STAGE IV |

**Figure 3 Modified operative link on intestinal metaplasia assessment staging frame (with exclusion of the biopsies from incisura angularis)[**[**16**](#_ENREF_16)**].** IM: Intestinal metaplasia.

**Table 1 Clinicopathological characteristics and endoscopic gastric atrophy classification**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **EGC group** | **Non-EGC group** | ***P* vaule** |
| Total patients, *n* (%) | 71 (100) | 156 (100) |  |
| Sex, *n* (%) |  |  | > 0.05 |
| Male | 51 (71.8) | 98 (62.8) |  |
| Female | 20 (28.2) | 58 (37.2) |  |
| Age, yr | 64.0 ± 9.1 | 62.2 ± 7.4 | > 0.05 |
| *Hp.* infection rate | 70.4% | 61.5% | > 0.05 |
| EGA classification |  |  | < 0.001 |
| C0 | 1 | 6 |  |
| C1 | 3 | 18 |  |
| C2 | 21 | 62 |  |
| C3 | 7 | 29 |  |
| O1 | 23 | 30 |  |
| O2 | 12 | 11 |  |
| O3 | 4 | 0 |  |
| Atrophic rate | 98.6% | 96.2% | > 0.05 |
| OLGA stage |  |  | < 0.001 |
| 0 | 1 | 6 |  |
| I | 16 | 65 |  |
| II | 17 | 49 |  |
| III | 27 | 27 |  |
| IV | 10 | 9 |  |
| OLGIM stage |  |  | < 0.001 |
| 0 | 6 | 45 |  |
| I | 17 | 47 |  |
| II | 18 | 33 |  |
| III | 20 | 23 |  |
| IV | 10 | 8 |  |
| IM rate | 91.5% | 71.2% | 0.001 |
| IM subtype |  |  | 0.019 |
| Complete  IM | 13 | 41 |  |
| Incomplete  IM | 52 | 70 |  |

EGA: Endoscopic gastric atrophy; EGC: Early gastric cancer; *H. pylori*: *Helicobacter pylori;* IM: Intestinal metaplasia; OLGA: Operative Link for Gas­tritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment.

**Table 2 Endoscopic gastric atrophy classification, OLGA/OLGIM stage in early gastric cancer and non-** **early gastric cancer patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **EGC group** | **Non-EGC group** | | ***P* vaule** | **OR (95%CI)** |
| EGA classification1 |  | |  | 0.005 | 2.26 (1.27-4.04) |
| None-to-mild | 25 | | 86 |  |  |
| Moderate-to-severe | 46 | | 70 |  |  |
| OLGA stage |  | |  | < 0.001 | 3.76 (2.07-6.85) |
| 0-II | 34 | | 121 |  |  |
| III-IV | 37 | | 35 |  |  |
| OLGIM stage |  | |  | < 0.001 | 2.95 (1.60-5.45) |
| 0-II | 41 | | 125 |  |  |
| III-IV | 30 | | 31 |  |  |

1None-to-mild EGA, C0-C2 type of EGA classification; Moderate-to-severe EGA, C3-O3 type of EGA classification. CI: Confidence interval; EGA: Endoscopic gastric atrophy; EGC: Early gastric cancer; OLGA: Operative Link for Gas­tritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment; OR: Odds ratio.

**Table 3 Relation between early gastric cancer classification and OLGA/OLGIM stage *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **EGA classification** | | ***P* vaule** |
|  | **None-to-mild** | **Moderate-to-severe** |
| OLGA stage |  |  | 0.001 |
| 0-II | 87 (56.1) | 68 (43.9) |  |
| III-IV | 24 (33.3) | 48 (66.7) |  |
| OLGIM stage |  |  | < 0.001 |
| 0-II | 94 (56.6) | 72 (43.4) |  |
| III-IV | 17 (27.9) | 44 (72.1) |  |

EGA: Endoscopic gastric atrophy; OLGA: Operative Link for Gas­tritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment.

**Table 4 Relation between OLGA/OLGIM stage and IM stage**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **OLGIM** | | | | | |
|  |  | Stage 0 | Stage I | Stage II | Stage III | Stage IV |
| OLGA | Stage 0 | 7 | 0 | 0 | 0 | 0 |
| Stage I | 29 | 41 | 8 | 3 | 0 |
| Stage II | 14 | 15 | 32 | 5 | 0 |
| Stage III | 1 | 7 | 10 | 33 | 3 |
| Stage IV | 0 | 1 | 1 | 2 | 15 |

OLGA: Operative Link for Gas­tritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment.

**Table 5 Logistic regression analysis of three risk factors for early gastric cancer**

|  |  |  |
| --- | --- | --- |
|  | **OR (95% CI)** | ***P* vaule** |
| Moderate-to-severe EGA | 1.95 (1.06-3.58) | 0.031 |
| OLGA stage III-IV | 3.14 (1.71-5.81) | < 0.001 |
| OLGIM stage III-IV | - | 0.781 |

CI: Confidence interval; EGA: Endoscopic gastric atrophy; EGC: Early gastric cancer; OLGA: perative Link for Gas­tritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment; OR: Odds ratio.

**Table 6 Comparison of *H. pylori* infection rates between different groups**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Group** | ***H. pylori* infection rate** | ***P* vaule** |
| EGA classification | None-mild degree | 54.1% | 0.001 |
| Moderate-severe degree | 75.0% |
| OLGA stage | 0-II | 55.8% | < 0.001 |
| III-IV | 83.6% |
| OLGIM stage | 0-II | 57.8% | < 0.001 |
| III-IV | 83.6% |
| IM subtype | Complete | 68.5% | 0.949 |
| Incomplete | 68.0% |

EGA: Endoscopic gastric atrophy; EGC: Early gastric cancer; IM: Intestinal metaplasia; OLGA: Operative Link for Gas­tritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment.